Status:
COMPLETED
The Effect Of Tafamidis For The Transthyretin Amyloid Polyneuropathy Patients With V30M Or Non-V30M Transthyretin
Lead Sponsor:
Pfizer
Conditions:
Transthyretin Familial Amyloid Polyneuropathy
Eligibility:
All Genders
20-75 years
Phase:
PHASE3
Brief Summary
Tafamidis has been developed as an oral specific stabilizer of transthyretin tetramer.
Eligibility Criteria
Inclusion
- Transthyretin amyloid polyneuropathy with V30M or non-V30M transthyretin mutation.
- Subject had amyloid documented by biopsy in accordance with institutional site standard of care.
Exclusion
- Primary amyloidosis and secondary amyloidosis.
- History of liver transplant.
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01435655
Start Date
November 1 2011
End Date
February 1 2014
Last Update
September 9 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Kumamoto University Hospital/Department of Neurology
Kumamoto, Kumamoto, Japan, 860-8556
2
Shinshu University Hospital/Department of Medicine (Neurology and Reumatology)
Matsumoto-shi, Nagano, Japan, 390-8621